Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 42


Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L.

JAMA. 2010 Sep 8;304(10):1082-90. doi: 10.1001/jama.2010.1278.


Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ.

J Infect Dis. 2010 Apr 15;201(8):1121-31. doi: 10.1086/651454.


Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.


Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program.

Wallis CL, Erasmus L, Varughese S, Ndiweni D, Stevens WS.

Pediatr Infect Dis J. 2009 Dec;28(12):1123-5. doi: 10.1097/INF.0b013e3181af5a00.


Protease inhibitor resistance in South African children with virologic failure.

van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W.

Pediatr Infect Dis J. 2009 Dec;28(12):1125-7. doi: 10.1097/INF.0b013e3181af829d.


Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

Soares EA, Santos AF, Gonzalez LM, Lalonde MS, Tebit DM, Tanuri A, Arts EJ, Soares MA.

J Antimicrob Chemother. 2009 Nov;64(5):938-44. doi: 10.1093/jac/dkp315. Epub 2009 Aug 26.


Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy.

Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, Barry G, Strehlau R, Sherman G, Abrams EJ.

AIDS. 2009 Jun 1;23(9):1097-107. doi: 10.1097/QAD.0b013e32832afefc.


Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.


Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L.

Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486.


Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008.

Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2008 Dec 5;57(RR-10):1-12.


Early antiretroviral therapy and mortality among HIV-infected infants.

Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA; CHER Study Team.

N Engl J Med. 2008 Nov 20;359(21):2233-44. doi: 10.1056/NEJMoa0800971.


Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.


Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P.

AIDS. 2008 Jul 11;22(11):1333-43. doi: 10.1097/QAD.0b013e32830437df.


Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.

Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, Bennett DE, Puren A, Morris L.

Antivir Ther. 2008;13 Suppl 2:101-7.


Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.


Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.


Challenges to pediatric HIV care and treatment in South Africa.

Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G.

J Infect Dis. 2007 Dec 1;196 Suppl 3:S474-81. doi: 10.1086/521116. Review.


Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.

Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, Bombana E, Suter F.

HIV Clin Trials. 2007 Sep-Oct;8(5):282-92.


Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.


Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.

Renaud-Théry F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, Perriëns J.

AIDS. 2007 Jul;21 Suppl 4:S89-95.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk